Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
N. Engl. J. Med 2021 Feb 13;[EPub Ahead of Print], R Motzer, B Alekseev, S-Y Rha, et alRenal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.